In patients with IIIA non-small cell lung cancer after neoadjuvant pembrolizumab and chemotherapy, LAMP3+ DCs involved in the process of lymphocytes recruitment and regulation, its increased levels were found to be associated with positive clinical outcomes by single-cell profiling (44). The gene discussed is LAMP3; the disease is non-small cell lung carcinoma.